Loading...

Mesoblast Limited

MESONASDAQ
Healthcare
Biotechnology
$15.93
$-0.43(-2.63%)

Mesoblast Limited (MESO) Stock Overview

Explore Mesoblast Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.3/100

Key Financials

Market Cap2B
P/E Ratio-17.58
EPS (TTM)$-1.34
ROE-0.22%
Fundamental Analysis

AI Price Forecasts

1 Week$10.82
1 Month$11.10
3 Months$19.92
1 Year Target$15.89

MESO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Mesoblast Limited (MESO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.76, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $15.89.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -17.58 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;